

Characterization of Late-Onset Parkinson’s Disease Human iPSC Line, Male, SCTi016-A

Catalog # 200-1069
Lot # 2512408007

Table of Contents

Product and Cell Line Information ... 3
Recommended Culture Conditions ... 4
Donor Information ... 5
Results Summary ... 6
Morphology Report ... 7
Viability and Recovery Report ... 8
Cell Line Identity Report ... 9
Sterility Report ... 11
Mycoplasma Report ... 12
Viral Screen Report ... 13
Parent Cell Lineage Determination Report ... 14
Chromosome Analysis Report ... 15
20q Status Report ... 16
Copy Number Variants (CNV) Report ... 17
Ancestry Report ... 19
Genetic Variants Report ... 21
TP53 and *BCOR* Status Report ... 23
Undifferentiated Status Report ... 25
Pluripotency Report ... 26

STEMCELL™ TECHNOLOGIES

Product Information

Product	Late-Onset Parkinson’s Disease Human iPSC Line, Male, SCTi016-A
Catalog #	200-1069
Lot #	2512408007
Format	~1 million viable cells per vial
Date Vialed	2025-12-14
Country of Manufacture	US
Stability, Storage, and Use Information	Product stable at -135°C or colder for 12 months from date of receipt. Thawed samples must be used immediately. Product is derived from cells or tissues that are collected using consent forms and protocols approved by either an Institutional Review Board, the Food and Drug Administration, the U.S. Department of Health and Human Services, and/or an equivalent regulatory authority. FOR IN VITRO RESEARCH USE ONLY. NOT APPROVED FOR DIAGNOSTIC, THERAPEUTIC, OR CLINICAL APPLICATIONS. NOT APPROVED FOR HUMAN OR VETERINARY USE IN VIVO.

Cell Line Information

Cell Line Name	SCTi016-A
Parent Material	SCTi016-A
Disease Associated Mutations	None detected (sporadic)
Cell Type	Human Induced Pluripotent Stem Cell (hiPSC)
Passage Number of Cell Banks*	**Working Cell Bank**: Passage 19 **Commercial Cell Bank**: Passage 22 *This vial is from a SCTi016-A commercial cell bank and was cultured for 21 passages prior to cryopreservation. +1 is added to the passage number on the vial to best represent the overall passage number of the cells at thaw.
Source Cell Tissue	Blood
Source Cell Type	Peripheral Blood Mononuclear Cell (PBMC); T Cell
Reprogramming Vector	Non-Integrating

Recommended Culture Conditions

Maintenance Medium	mTeSR™ Plus (Cat # 100-0276)
Culture Type	Adherent
Supplement	Not Required
Substrate	Corning® Matrigel® hESC-Qualified Matrix
Dissociation Reagent	ReLeSR™ (Cat # 100-0484)
Dissociation Method	Non-enzymatic aggregate dissociation
Split Ratio	1:60 - 1:100 every 6 - 8 days
Incubator Atmosphere	37°C, 5% CO_2, and 95% humidity
Cryopreservation Reagent	CryoStor® CS10 (Cat # 07930/100-1061)
Thaw Recommendation	After thaw, pellet cells and resuspend in 1 mL mTeSR™ Plus. Aliquot into a pre-prepared six-well plate at six different densities: 150 µL, 100 µL, 75 µL, 50 µL, 25 µL, and 15 µL. Select the well with optimal colony density for passaging at Day 6 - 8.

Culture conditions are reflective of how the cell line was maintained prior to cryopreservation.

Donor Information

Age*	61	
Sex†	Male	
Ethnicity and/or Race*	White/Declined to state	
Ancestry†	0% African 30.3% European	0% East Asian 69.7% South Asian
Diagnosis‡	Late-Onset Parkinson's Disease	
Age at Symptom Onset‡	60	
Height†	178 cm	
Weight†	81.7 kg	
BMI†	25.8 kg/m^2	
Blood Type†	A+	
Tobacco Use*	Non-Smoker	
HLA Haplotype†	HLA Class I: A*01:01:01G, 29:02:01G B*14:01:01, 41:01:01 C*08:02:01G, 17:01:01G E*01:01:01G, - F*01:01:01G, - G*01:01:01G, 01:01:02G	HLA Class II: DRB1*01:01:01G, 13:02:01 DRB3*03:01:01G, - DRB4*-, - DQA1*01:01:01G, 01:02:01G DQB1*05:01:01G, 06:04:01G DPA1*01:03:01G, - DPB1*04:01:01G, -

* Self-declared
† Calculated
‡ Clinically documented

STEMCELL™ TECHNOLOGIES

Results Summary

Assessment	Analytical Method	Acceptance Criteria	Result
Viability[CCB]	Viability assessment performed on thawed cells using the NucleoCounter® NC-250™ by ChemoMetec	≥ 60% viable	Pass
Recovery[CCB]	Cells recovered using specified thaw and culture recommendations	Recoverable attachment 24 hr. after plating and cells grow to confluency	Pass
Cell Line Identity[CCB]	STR amplification performed using the Powerplex 16 HS System by Promega	Match	Pass
Sterility[CCB]	Presence or absence of bacterial and fungal organisms by incubation in TSB and FTB for 14 days	Negative	Pass
Mycoplasma[CCB]	Presence or absence of mycoplasma using the EZ-PCR™ Mycoplasma Detection Kit by Sartorius	Negative	Pass
Viral Screen[PMB]	Human Comprehensive CLEAR PCR Panel	Negative	Pass
Parental Cell Lineage[PMB]	Presence or absence of TCR Gene Rearrangements using the T cell clonality assay	No specification	Reported
Residual Vector[PMB]	Genomic DNA analyzed by PCR	Negative	Pass
Karyotype[CCB]	GTL Banding performed on 20 metaphase cells	Normal	Pass
20q Amplification[CCB]	Fluorescence in situ hybridization (FISH)	Negative	Pass
Copy Number Variants[CCB]	Genomic DNA analyzed using Illumina Global Diversity Array with Cytogenetics-8 (GDACyto)	No Specification	Reported
Ancestry[WCB]	Whole exome and whole genome sequencing data analyzed using EthSeq	No specification	Reported
Genetic Variants[WCB]	Whole exome and whole genome sequencing data analyzed using ClinVar	No Specification	Reported
***TP53* and *BCOR* Status**[WCB]	Whole exome and whole genome sequencing data analyzed using ClinVar	No Specification	Reported
Undifferentiated Status[CCB]	Three-passage assay and flow cytometry for undifferentiated cell markers	OCT4+, TRA-1-60+ ≥ 80%	Pass
Pluripotency[WCB]	Flow cytometry performed on cells differentiated into endoderm, mesoderm, and ectoderm germ layers	**Endoderm:** CXCR4+, SOX17+ ≥ 70% **Mesoderm:** T+, NCAM+ ≥ 70% **Ectoderm:** PAX6+, NESTIN+ ≥ 70%	Pass

[CCB]Assessment performed on the Commercial Cell Bank
[WCB]Assessment performed on the Working Cell Bank
[MCB]Assessment performed on the Master Cell Bank
[PMB]Assessment performed prior to the Master Cell Bank

X VM 2026-06-05

Approved by Initial & Date

STEMCELL™ TECHNOLOGIES

Morphology Report

Sample	SCTi016-A Lot # 2512408007
Submitted Passage #	25
Analysis Date	2026-03-04

Results:





Interpretation:
Sample demonstrated round colonies containing tightly packed cells with a high nucleus-to-cytoplasm ratio and prominent nucleoli. Colony centers were dense and appeared bright under a phase contrast microscope. This morphology is consistent with the undifferentiated state.

Assay Description:
Sample is thawed as described in the Product Information Sheet and cultured in mTeSR™ Plus (#100-0276) on Corning® Matrigel® hESC-Qualified Matrix for three passages using ReLeSR™ (#100-0484). Images are captured at 20X and 40X magnification on Day 7 of Passage 3.

Viability and Recovery Report

Sample	SCTi016-A Lot # 2512408007
Viability Platform	NucleoCounter® NC-250™
Viability Protocol	Viability and Cell Count - A100 and B Assay
Viability Analysis Date	2026-02-04
Recovery Completion Date	2026-02-11

Results:

Viability	80.6%
Recovery after 24h	☒
Cells Grow to Confluence	☒

Assay Description:
Viability: iPSC aggregates are analyzed at thaw using the NucleoCounter® NC-250™ Viability and Cell Count - A100 and B Assay. Cell aggregates are disaggregated, singularized, and stained with DAPI. Viability % represents the mean of two counts.

Recovery: Sample is thawed and recovered as described in the Product Information Sheet. At 24 h after thaw, the culture is assessed for the number of adherent cellular aggregates. Cells are expanded until the culture reaches an optimal density consisting of large, multilayered colonies that have begun to merge.

Cell Line Identity Report

	SCTi016-A Lot # 2512408007	SCTi016-A Pre-Master Cell Bank
Samples Received Date	2026-01-07	2026-01-07
STR Amplification Date	2026-01-20	2026-01-13

Short Tandem Repeat (STR) Analysis

Sample Name	SCTi016-A Lot # 2512408007	SCTi016-A Pre-Master Cell Bank
CTR No. †	110277	110268
FGA	18, 24	18, 24
TPOX	11, 11	11, 11
D8S1179	12, 13	12, 13
vWA	16, 17	16, 17
Amelogenin	X, Y	X, Y
Penta_D	9, 13	9, 13
CSF1PO	10, 12	10, 12
D16S539	11, 14	11, 14
D7S820	10, 12	10, 12
D13S317	11, 11	11, 11
D5S818	11, 12	11, 12
Penta_E	7, 12	7, 12
D18S51	15, MV	15, MV
D21S11	29, 31.2	29, 31.2
TH01	6, 9	6, 9
D3S1358	15, 16	15, 16
Allelic Polymorphisms	28	28
Matches*	110268	110277
Comments	Microvariant	Microvariant

†CTR No.: Characterization Test Request Number; also known as a laboratory accessioning number.
*Note: The STR profile of the following sample is a 100% match for the given sample/samples.

STEMCELL™ TECHNOLOGIES

Cell Line Identity Report (cont.)

Assay Description:
STR Analysis is performed using the PowerPlex 16 HS System by Promega™. Results are reported as 13 CODIS STR markers, Amelogenin for sex determination and two low-stutter, highly discriminating pentanucleotide STR markers.

Results:
The genotypic profiles comprise a range of 28 allelic polymorphisms across the 15 STR loci analyzed.

Interpretation:
The concentration of DNA required to achieve an acceptable STR genotype (signal/noise) was equivalent to that required for the standard procedure (~1 ng/amplification reaction) from human genomic DNA. These results suggest that the cells submitted correspond to the cell lines as named and were not contaminated with any other human cells or a significant amount of mouse feeder layer cells. Samples 110268 and 110277 each have a microvariant at the D18S51 loci with a size of 313.37 and 313.45 bp, respectively.

Sensitivity:
Sensitivity limits for detection of STR polymorphisms unique to either this or other human cell lines is ~2 - 4%.

Sterility Report

Collection Date	2025-12-18
Approval Date	2026-01-02

Diagnostic Summary

Test	Colony	Tested	+	+/-	?	PDG
All results NEGATIVE						

+ = Positive; +/- = Equivocal; ? = Indeterminate; PDG = Pending

Bacteriology – Sterility Test – Broth Cultures: 2 Samples

	SCTi016-A Lot # 2512408007 Cryovial 1	SCTi016-A Lot # 2512408007 Cryovial 2
Sterility Test (TSB, FTM)	-	-

Remarks:
- = Negative/No Growth as determined by culture conditions; + = Positive/Growth Present
NE = Not Evaluated: Samples evaluated on scheduled business days; NI = Not Interpreted: Culture could not be interpreted due to overgrowth of Proteus; NT = Not Tested; TSB = Tryptic soy broth; FTM = Fluid thioglycollate media.

Mycoplasma Report

Date Reported	2026-01-24
Assay Description	Sample is tested for presence of mycoplasma using EZ-PCR™ Mycoplasma Detection Kit (Sartorius).

Sample Name	Result	Interpretation
SCTi016-A **Lot # 2512408007**	Negative	Band was not seen at 270bp, indicating the absence of mycoplasma
Positive (+) Control	Positive	
Negative (-) Control	Negative	

Viral Screen Report

Collection Date	2025-11-20
Approval Date	2025-11-24

Molecular Diagnostics – Infectious Disease PCR
Human Comprehensive CLEAR Panel

	SCTi016-A Pre-Master Cell Bank
AAV2 (Adeno-Associated Virus 2)	-
BK Virus	-
Epstein-Barr Virus	-
Hantaan PCR	-
Hepatitis A Virus	-
Hepatitis B Virus	-
Hepatitis C Virus	-
Herpes Simplex Virus 1 PCR	-
Herpes Simplex Virus 2 PCR	-
Herpes Virus Type 6	-
Herpes Virus Type 7	-
Herpes Virus Type 8	-
HIV-1	-
HIV-2	-

	SCTi016-A Pre-Master Cell Bank
HPV-16	-
HPV-18	-
Human Adenovirus PCR	-
Human Cytomegalovirus	-
Human Foamy Virus	-
Human T-Lymphotropic Virus	-
John Cunningham Virus	-
LCMV PCR	-
Parvovirus B19	-
Sarbecovirus (SARs Virus) PCR	-
Seoul Virus PCR	-
C. bovis PCR	-
Mycoplasma Genus PCR	-

Remarks:
- = Negative; +/- = Equivocal; + = Positive; I = Inconclusive
An equivocal result indicates inconsistent amplification detected by real-time PCR.
Inconclusive indicates failure of control result.

Nucleic Acid Recovery Control (NRC)/Inhibition Control: A low copy exogenous nucleic acid was added to sample lysis prior to nucleic acid isolation to serve as both a control to monitor for nucleic acid recovery and PCR inhibition. An RNA NRC also monitors reverse transcription for RNA virus assays. Nucleic acid recovery and PCR inhibition is monitored by a PCR assay specific for the NRC template. Unless otherwise stated, control results passed for this order.

Any samples reported as equivocal or positive result in this report has been confirmed by re-extracting nucleic acid and repeating real-time PCR amplification to confirm the initial testing result.

Parent Cell Lineage Determination Report

T-Cell Receptor (TCR) Gene Rearrangement Analysis (Blood-derived cell lines only)

	TCR-αβ		TCR-γδ	
T Cell Clonality Assay:	☒Positive	☐Negative	☒Positive	☐Negative
Final Result:	☒T Cell Derived	☐Non-T Cell Derived	☐TBD	☐N/A

Assay Description:
Genomic DNA is extracted using the KingFisher Duo Prime Purification System (Thermo Scientific) and isolated using the MagMAX DNA Multi-Sample Ultra 2.0 Kit (Applied Biosystems), then resuspended to a final concentration of 100 µg/mL – 400 µg/mL in elution buffer. Using the TCRB + TCRG T-Cell Clonality Assay for Gel Detection (Invivoscribe), PCR is then carried out as per the manufacturer's protocol. The T-Cell Clonality Assay uses multiple consensus DNA primers which target conserved regions within the T-cell receptor β chain and γ chain genes, including the conserved framework, diversity, and joining regions. PCR products are analyzed using 6% Tris-borate-EDTA (TBE) gel electrophoresis with a 100bp ladder and gel red staining. Clonality is indicated as positive if any of the master mixes generate clonal band(s), and negative if no clonal band(s) are generated. For further details regarding clonal band product size, please refer to the TCRB + TCRG T-Cell Clonality Assay manual.

Reference:
Invivoscribe (2019) Instructions for Use TCRB + TCRG T-Cell Clonality Assay. Rev. G:3-15.

Chromosome Analysis Report

GTL-Banded Karyotype Analysis

Date Reported	2026-01-10
Sample	SCTi016-A Lot # 2512408007
Cell Line Sex	Male
Submitted Passage #	22
Date of Sample	2026-01-07
Specimen	Human iPSC
Results	46,XY



Cell	29
Slide	1
Slide Type	Karyotype
Total Counted	20
Total Analyzed	20
Total Karyogrammed	20
Band Resolution	500

Interpretation:
This is a normal karyotype; no clonal abnormalities were detected at the stated band level of resolution.

Limitations:
This assay allows for microscopic visualization of numerical and structural chromosome abnormalities. The size of structural abnormality that can be detected is > 3 - 10Mb, dependent upon the G-band resolution obtained from this specimen. For the purposes of this report, band level is defined as the number of G-bands per haploid genome. It is documented here as "band level", i.e., the range of bands determined from the twenty karyograms in this assay. Detection of heterogeneity of clonal cell populations in this specimen (i.e., mosaicism) is limited by the number of metaphase cells examined, documented here as "# of cells counted".

20q Status Report

Fluorescence In-Situ Hybridization (FISH) Analysis

Date Reported	2025-12-23
Sample	SCTi016-A Lot # 2512408007
Cell Line Sex	Male
Submitted Passage #	22
Date of Sample	2025-12-18
Specimen	Human iPSC

Probe	# of cells with 2R2G pattern	# of cells with 1R2G pattern	# of cells with 1R1G pattern	# of cells with 2R1G pattern	# of cells with 3R3G pattern
20p11 (G) / BCL2L1 (R)	191 / 200 (95.5%)	1 / 200 (0.5%)	4 / 200 (2.0%)	2 / 200 (1.0%)	2 / 200 (1.0%)
Cutoff	N/A	4%	4%	4%	3%

Probe: 20p11 (G) / 20q11.21 (R)



Interpretation:
There is no evidence for aneusomy of chromosome 20. Two probe signals were observed in 95.5% of two hundred interphase cells examined for the 20p11.21 and 20q11.21 (BCL2L1) regions.

STEMCELL™ TECHNOLOGIES

Copy Number Variants (CNV) Report

Microarray Analysis

Date Reported	2026-02-16
Sample	SCTi016-A Lot # 2512408007
Cell Line Sex	Male
Submitted Passage #	22
Date of Sample	2026-01-07
Specimen	Human iPSC

Microarray Results arr(X,Y)x1,(1-22)x2

Call Table:

Chr	Cytoband	Event (% Mosaic)	Estimated Copy Number	Start	End	Length (Base Pairs)	Gene Count
2	2p25.3 - p25.2	Loss	1	4,353,669	4,453,136	99,468	0
5	5q14.3	Loss	1	84,053,966	84,097,490	43,525	0
7	7p14.1	Homozygous Loss	0	38,293,984	38,338,251	44,268	1
7	7p14.1	Loss	1	38,339,539	38,374,589	35,051	0
7	7q34	Loss	1	142,326,241	142,495,156	168,916	1
14	14q11.2	Loss	1	22,327,490	22,580,859	253,370	0
14	14q11.2	Homozygous Loss	0	22,582,397	22,971,137	388,741	1
14	14q21.1	Loss	1	40,367,540	40,399,654	32,115	0
17	17p13.2	Loss	1	3,463,075	3,491,622	28,548	1

Interpretation:
There were 0 reportable copy number changes as well as 0 reportable regions of LOH identified:

Copy Number Variants (CNV) Report (cont.)

Specifications:

- Platform: Illumina: Global Diversity Array with Cytogenetics-8 (GDACyto)
- Marker coverage: 1,825,277 spanning whole human genome
- Analysis software: Bionano: Via™ Software
- Array design, genomic position, genes and chromosome banding are based on genome build GRCh37/hg19.
- Aberrant copy number genomic regions are identified by log R ratio (LRR) and B allele frequency (BAF). LRR is the log ratio of observed probe intensity to expected intensity, deviations from zero are evidence for copy number change. BAF is the proportion of hybridized sample that carries the B allele: 0.0, 0.5, and 1.0 are expected for each locus in a normal sample. Deviations from this expectation are indicative of aberrant copy number.
- Quality assurance monitors: 1) Call Rate; 2) Confidence Threshold; 3) LogRDev; 4) Illumina sample dependent/independent QC measures.
- Reportable copy number changes are gains or losses greater than 400kb. Reportable regions of LOH are greater than 5Mb. See Interpretation for copy number changes and regions of LOH that meet these criteria. See Call Table for all copy number changes identified by the analysis software. If mosaicism is detected, the approximate percentage of mosaicism is listed in the 'Event (% Mosaic)' column.
- Copy number changes and regions of LOH are reported at greater than 10% and 20% mosaicism respectively.
- The assay is currently validated for the detection of copy number losses greater than 20kb in size and copy number gains 50kb in size (smaller changes may be detected depending on gene content and probe number but will not be included in the Call Table). From validation studies, abnormalities present in a mosaic state are reliably detected if the mosaicism level (percentage of abnormal cells) is 20% or higher.
- Fluorescence type and intensity of each probe is compared to a custom cluster file using Illumina's Beeline or iScan control software.

Limitations:

This assay will detect aneuploidy, deletions, and duplications of represented loci, and regions of loss/absence of heterozygosity (LOH), but will not detect balanced alterations (reciprocal translocations, Robertsonian translocations, inversions, and insertions), or point mutations. Based on the results of internal validation studies, abnormalities present in a mosaic state are reliably detected if the mosaicism level (percentage of abnormal cells) is 20% or higher. The failure to detect an alteration at any locus does not exclude all anomalies at that locus. Significance of the number of probes used to detect an aberration has not been determined and confirmational testing may be informative. Actual chromosomal localization of copy number change is not determined by this assay. Other mapping procedures are required for determining chromosomal localization.

Ancestry Report

Sample	SCTi016-A Working Cell Bank
Whole Exome and Whole Genome Sequencing Report Date	2026-02-20



EthSEQ Reference Database	Ancestry and contribution	Chart
EthSEQ Reference Database	**Ancestry:** South Asian **Type:** Closest **Contribution:** European: 30.33% South Asian: 69.67%	

Ancestry Report (cont.)

Analysis Description:

Sequencing and Analysis Workflow:

Genomic DNA from the sample underwent whole-genome sequencing (WGS) using the NovaSeq X Plus System (Illumina), generating paired-end 150 bp reads at an average coverage of 50x across the genome. Prior to sequencing, DNA was randomly fragmented, end-repaired, A-tailed, and ligated with Illumina adapters. The adapter-ligated fragments were size-selected, PCR-amplified, and purified to generate the final sequencing libraries. To further enhance variant detection in coding regions, whole-exome capture was performed using the SureSelect Human All Exon V6 kit (Agilent Technologies), enriching for ~60 Mb of exonic and splice junction regions across approximately 20,000 human genes. Sequencing reads were aligned to the GRCh38 human reference genome, and single nucleotide variants (SNVs) and insertions/deletions (indels) were identified following the GATK best practices (v4.6.1.0).

Ancestry was calculated using the EthSEQ R package (v3.0.2) and a reference model described by Romanel et al. (2017). The reference model included genotype data from 233,887 loci representing individuals with known ancestries, categorized into four major populations: African, European, South Asian, and East Asian. If a sample's ancestry fell within one of these ancestral groups, it was reported as "Inside." If the sample's ancestry lay outside the predefined groups, the nearest ancestry was reported as "Closest."

Reference:

Romanel, A. et al. (2017) EthSEQ: ethnicity annotation from whole exome sequencing data. Bioinformatics. 33(15):2402-04.

Genetic Variants Report

Sample	SCTi016-A Working Cell Bank
Whole Exome and Whole Genome Sequencing Report Date	2026-02-20
ClinVar Version Date	2024-02-15

Pathogenic or Likely Pathogenic Variants:

Gene	ClinVar ID	Coordinates	Molecular Consequence	Nucleotide Change	Protein Change
AMPD1	18271	chr1:114693436	Nonsense	c.34C>T	Q12*
CAPN3	281689	chr15:42410981	Frameshift variant	c.2361_2362insTC	R788fs
CAPN3	281686	chr15:42410982	Frameshift variant	c.2362_2363insTC	R788fs
COL4A4	191312	chr2:227028004	Missense variant	c.3979G>A	V1327M
CYP17A1	1788	chr10:102832577	Missense variant	c.1073G>A	R358Q
DCAF17	191260	chr2:171448667	Intron variant	c.322-14C>T	
ERCC1,POLR1G	235480	chr19:45408812	Missense variant	c.844A>G	T284A
HFE,HFE-AS1	10	chr6:26090951	Missense variant	c.187C>G	H63D
ITPKB	1705897	chr1:226735804	Missense variant	c.1655C>A	P552Q
ITPKB	1705899	chr1:226736237	Missense variant	c.1222T>G	S408A
PRF1	13718	chr10:70600631	Missense variant	c.272C>T	A91V
PTEN	810888	chr10:87863959	Missense variant	c.-511G>A	G4R
SLC3A1,PREPL	336214	chr2:44320435	Missense variant	c.1854G>A	M618I
TCF3	1167884	chr19:1619351	Missense variant	c.1291G>A	G431S
TUBB2B	381699	chr6:3225346	Missense variant	c.743C>T	A248V
TYR	3778	chr11:89178528	Missense variant	c.575C>A	S192Y

Genetic Variants Report (cont.)

Analysis Description:

Sequencing and Analysis Workflow:

Genomic DNA from the sample underwent whole-genome sequencing (WGS) using the NovaSeq X Plus System (Illumina), generating paired-end 150 bp reads at an average coverage of 50x across the genome. Prior to sequencing, DNA was randomly fragmented, end-repaired, A-tailed, and ligated with Illumina adapters. The adapter-ligated fragments were size-selected, PCR-amplified, and purified to generate the final sequencing libraries. To further enhance variant detection in coding regions, whole-exome capture was performed using the SureSelect Human All Exon V6 kit (Agilent Technologies), enriching for ~60 Mb of exonic and splice junction regions across approximately 20,000 human genes. Sequencing reads were aligned to the GRCh38 human reference genome, and single nucleotide variants (SNVs) and insertions/deletions (indels) were identified following GATK best practices (v4.6.1.0).

Variant Filtering and Classification:

Single nucleotide variants (SNVs) and insertions/deletions (indels) were retained if they met the convolutional neural network (CNN) filtering threshold and were supported by a minimum of two sequencing reads. All retained variants were cross-referenced against ClinVar (version 2024-02), a publicly available database curated by the NCBI that links human genetic variants to associated phenotypes. Only variants classified by ClinVar as *pathogenic* or *likely pathogenic* were included in this report.

Disclaimer:

Pathogenicity classifications are based solely on ClinVar annotations and have not been independently validated by STEMCELL. Classifications reflect the state of knowledge at the time of reporting and may be subject to change as new evidence emerges.

TP53 and *BCOR* Status Report

Sample	SCTi016-A Working Cell Bank
Whole Exome and Whole Genome Sequencing Report Date	2026-02-20
ClinVar Version Date	2024-02-15

Overview:

Gene	% Exon Covered by 15+ Reads	Average Exonic Read Depth	# Exonic or Impact Variants Detected
TP53	100.00%	120.51 (sd:63.24)	1
BCOR	99.34%	70.21 (sd:42.04)	2

TP53:

Locus	ClinVar ID	Nucleotide Change	Protein Change	Variant Type	# Ref Reads	# Alt Reads	Inferred Inheritance
chr17:7676154	12351	c.215C>G	p.Pro72Arg	Missense variant	0	149	Germline homozygous

BCOR:

Locus	ClinVar ID	Nucleotide Change	Protein Change	Variant Type	# Ref Reads	# Alt Reads	Inferred Inheritance
chrX:40073654	95766	c.1692A>G	p.Ala564Ala	Synonymous variant	0	120	Germline homozygous
chrX:40074086	95764	c.1260T>C	p.Asp420Asp	Synonymous variant	0	132	Germline homozygous

TP53 and *BCOR* Status Report (cont.)

Interpretation:
No pathogenic or likely pathogenic variants were identified in *TP53* and *BCOR*. No variants were identified in *TP53* that were previously reported as common recurring mutations in human pluripotent stem cell cultures by Merkle et al. (2017).

Analysis Description:

Sequencing and Analysis Workflow:

Genomic DNA from the sample underwent whole-genome sequencing (WGS) using the NovaSeq X Plus System (Illumina), generating paired-end 150 bp reads at an average coverage of 50x across the genome. Prior to sequencing, DNA was randomly fragmented, end-repaired, A-tailed, and ligated with Illumina adapters. The adapter-ligated fragments were size-selected, PCR-amplified, and purified to generate the final sequencing libraries. To further enhance variant detection in coding regions, whole-exome capture was performed using the SureSelect Human All Exon V6 kit (Agilent Technologies), enriching for ~60 Mb of exonic and splice junction regions across approximately 20,000 human genes. Sequencing reads were aligned to the GRCh38 human reference genome, and single nucleotide variants (SNVs) and insertions/deletions (indels) were identified following GATK best practices (v4.6.1.0).

Variant Filtering and Classification:

Single nucleotide variants (SNVs) and insertions/deletions (indels) were retained if they met the convolutional neural network (CNN) filtering threshold and were supported by a minimum of two sequencing reads. All retained variants were cross-referenced against ClinVar (version 2024-02), a publicly available database curated by the NCBI that links human genetic variants to associated phenotypes. All exonic variants in the *TP53* and *BCOR* genes that meet these criteria and result in amino acid changes are reported. For *TP53*, variants are further cross-referenced with those described by Merkle et al. (2017).

Disclaimer:

Pathogenicity classifications are based solely on ClinVar annotations and have not been independently validated by STEMCELL. Classifications reflect the state of knowledge at the time of reporting and may be subject to change as new evidence emerges.

Reference:

Merkle, FT. et al. (2017) Human pluripotent stem cells recurrently acquire and expand dominant negative P53 mutations. Nature. 545(7653):229-233.

Undifferentiated Status Report

Flow Cytometric Analysis

Sample	SCTi016-A Lot # 2512408007
Submitted Passage #	25
Analysis Date	2026-03-04
# of Events Analyzed	10,000

Results:

Marker	Expression
OCT4	96.9%
TRA-1-60	99.6%

Interpretation:
Upon examination, a high percentage of cells exhibited OCT4 and TRA-1-60 markers of the undifferentiated status, indicative of a primarily undifferentiated cell culture.

Assay Description:
Sample is thawed and cultured for three consecutive passages, then singularized for undifferentiated marker expression analysis by flow cytometry at the end of passage 3. Results are analyzed using FlowJo™ software. Results are presented as the mean marker expression of two technical replicates.

Pluripotency Report

In Vitro Directed Trilineage Differentiation Analysis

Sample	SCTi016-A Working Cell Bank
Submitted Passage #	21
Analysis Date	2026-02-25

Results:

Lineage	Marker	Expression
Endoderm	SOX17	91.1%
	CXCR4	96.7%
Mesoderm	BRACHYURY (T)	98.9%
	NCAM	98.3%
Ectoderm	PAX6	97.0%
	NESTIN	97.7%

Interpretation:
Following directed differentiation, expression was observed for markers specific to each lineage: endoderm, mesoderm, and ectoderm. This result is consistent with the pluripotent state.

Assay Description:
Sample undergoes directed differentiation using the STEMdiff™ Definitive Endoderm Kit (Cat # 05110), STEMdiff™ Mesoderm Induction Medium (Cat # 05221), and the STEMdiff™ SMADi Neural Induction Kit (Cat # 08581). Expression of lineage-specific markers is assessed by flow cytometry following five days of culture for endoderm and mesoderm lineages, and following seven days of culture for the ectoderm lineage. Results are reported as the percent of total cells with positive expression for each individual lineage-specific marker. Results are presented as the mean marker expression of two technical replicates.